Dr. Chari on Comparing Agents in Multiple Myeloma

Ajai Chari, MD
Published: Monday, Nov 13, 2017



Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.

The median overall survival of multiple myeloma has been on the rise, in part due to the plethora of novel agents that have emerged.

With 9 drugs approved in the last decade, choosing among the various regimens and combinations can be overwhelming, says Chari. Comparing these agents though is not so simple, as there are many variables to any given trial.
 


Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.

The median overall survival of multiple myeloma has been on the rise, in part due to the plethora of novel agents that have emerged.

With 9 drugs approved in the last decade, choosing among the various regimens and combinations can be overwhelming, says Chari. Comparing these agents though is not so simple, as there are many variables to any given trial.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x